Prostate最新文献

{"title":"Impact of Concomitant Hormone Therapy on the Diagnostic Performance of ¹⁸F-Piflufolastat PET/CT in Prostate Cancer Patients: A Sub-Group Analysis of OSPREY Cohort B.","authors":"Lawrence Saperstein, Steven P Rowe, Michael A Gorin, Kenneth J Pienta, Barry A Siegel, Michael J Morris, Saradha Baskaran, Nancy Stambler, Vincent A DiPippo, Bela S Denes","doi":"10.1002/pros.24909","DOIUrl":"10.1002/pros.24909","url":null,"abstract":"<p><strong>Background: </strong>This study investigates the impact of hormone therapy (HT) on the diagnostic performance of ¹⁸F-piflufolastat PET/CT in OSPREY (NCT02981368) cohort B patients with recurrent or metastatic prostate cancer.</p><p><strong>Methods: </strong>¹⁸F-piflufolastat PET/CT was evaluated in OSPREY cohort B patients (n = 117 men) with elevated prostate-specific antigen (PSA) levels and suspected local recurrence or metastatic disease on baseline conventional imaging. Patients were stratified based on HT status, and sensitivity and positive predictive value (PPV) were determined for the subset of 93 patients with evaluable pathology. Baseline serum PSA and testosterone levels were determined within 30 days before dosing using standardized laboratory methods.</p><p><strong>Results: </strong>In OSPREY cohort B, 34.4% of patients (32/93) were on at least one concomitant HT with a median exposure duration of 15.5 months. The median baseline PSA and testosterone levels for patients on concurrent HT (n = 32) were 31.6 ng/mL and 9 ng/dL, respectively. For patients not on concurrent therapy (n = 61), median PSA and testosterone levels were 6.1 ng/mL and 317.35 ng/dL, respectively. The median sensitivity of ¹⁸F-piflufolastat PET/CT across three readers was 96.4% (95%CI: 80.8%-100%) in patients receiving concurrent HT and 95.4% (95%CI: 83.7%-99.6%) in patients not receiving concurrent HT. A modest increase in median PPV was observed in patients receiving concomitant HT (median of three readers: 90.0% [95%CI: 73.6, 97.3]) compared to patients not receiving concomitant therapy (median of three readers: 77.4% [95%CI: 66.1, 88.6]).</p><p><strong>Conclusions: </strong>The diagnostic performance of ¹⁸F-piflufolastat PET/CT was unaffected by concomitant HT in OSPREY cohort B patients with recurrent and/or metastatic prostate cancer.</p>","PeriodicalId":54544,"journal":{"name":"Prostate","volume":" ","pages":"1005-1015"},"PeriodicalIF":2.6,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12211537/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144053935","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Holmium Laser Enucleation of the Prostate on Active Surveillance for Prostate Cancer in Patients With Lower Urinary Tract Symptoms.","authors":"Charly Bâcle, Emilien Seizilles De Mazancourt, Nadia Abid, Alain Ruffion, Olivier Rouvière, Marc Colombel, Hakim Fassi-Fehri","doi":"10.1002/pros.24906","DOIUrl":"10.1002/pros.24906","url":null,"abstract":"<p><strong>Background: </strong>Active surveillance (AS) is a recommended strategy for low- or favorable intermediate-risk prostate cancers (PCa), avoiding more invasive treatments. However, the concurrent development of symptomatic benign prostatic hyperplasia (BPH) may necessitate holmium laser enucleation of the prostate (HoLEP). This study aims to evaluate the impact of HoLEP on patients under AS for PCa.</p><p><strong>Methods: </strong>Medical records of patients under AS for PCa diagnosed between 2010 and 2023 were retrospectively reviewed. Patients with a life expectancy of more than 10 years and a follow-up of at least 1 year were included. Functional and oncological outcomes, as well as follow-up data (PSA levels, PSA density (PSA-D), mpMRI, prostate biopsies), were collected. Patients who underwent HoLEP were compared to those who did not. The primary endpoint was discontinuation of AS.</p><p><strong>Results: </strong>A total of 310 patients under AS were included, of whom 62 (20%) underwent HoLEP. Prostate volume was higher in the HoLEP group than in the non-operated group (70 vs. 50 g, p < 0.0001), and PSA density was lower (0.09 vs. 0.12 p < 0.0001). The median enucleated volume was 62 mL (IQR 34-85). Grade group (GG) 1 and 2 prostate cancer was identified in enucleated pathology in 17 (27%) and 3 (5%) patients, respectively. No patient had a GG lesion ≥ 3 on the enucleated pathology. The rate of AS discontinuation was 18% in the HoLEP group vs. 56% in the control group (p < 0.01). Multivariate analysis identified HoLEP as a protective factor for continued AS (HR = 0.231; p < 0.0001). At last follow-up, PSA and PSA density were significantly lower in the HoLEP group (2 vs. 7.7 p < 0.0001 and 0.06 vs. 0.14 p < 0.0001, respectively).</p><p><strong>Conclusion: </strong>Performing HoLEP in patients under AS for PCa with LUTS due to BPH may reduce the risk of deferred prostate cancer treatment, without altering oncological outcomes or future treatment options. HoLEP significantly impacts AS parameters, modifying patient monitoring. Further studies are needed to confirm these findings and establish appropriate follow-up protocols.</p><p><strong>Trial registration: </strong>CNIL number 24-5016.</p>","PeriodicalId":54544,"journal":{"name":"Prostate","volume":" ","pages":"989-999"},"PeriodicalIF":2.6,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144026864","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Survival Outcomes for Rural Patients With Advanced Prostate Cancer: A SEER Investigation.","authors":"Liang G Qu, J Bailey Vaselkiv, Marlon Perera, Lorelei Mucci","doi":"10.1002/pros.24915","DOIUrl":"10.1002/pros.24915","url":null,"abstract":"<p><strong>Background: </strong>Differences may exist in survival for patients with de novo metastatic prostate cancer according to urban-rural status.</p><p><strong>Methods: </strong>This cohort study utilized the Surveillance, Epidemiology, and End Results database. Data on demographics, urban-rural status, histopathology, and survival were extracted for men aged ≤ 75 years, diagnosed with metastatic prostate cancer between 2009 and 2018. Patients missing rurality status or survival outcome-related data were excluded. Differences between urban and rural cohorts in overall and cancer-specific survival were analyzed using Cox regression and restricted mean survival time. Subgroup analyses were performed for variant histological subtypes of prostate cancer. Sensitivity analyses were performed for varying definitions of rurality.</p><p><strong>Results: </strong>Altogether, 21,290 participants were included. The cohorts of rural and urban participants differed in age, race, US region, and marital status. Cox regression failed to demonstrate associations between urban-rural status and overall survival (adjusted hazard ratio = 1.03, 95% confidence interval: 0.97-1.09) and cancer-specific survival (1.03, 0.97-1.10). Restricted mean survival time modeling demonstrated that urban patients lived 2.29 months longer than rural patients (95% confidence interval: 0.61-3.97). Sub-analyses of neuroendocrine, intraductal, and other histological subtypes, did not demonstrate any association between urban-rural status and overall survival. A more selective definition of rurality resulted in a persisting difference in overall survival (2.12 months, 0.24-4.01) through restricted mean survival time. Similarly, a broader definition of rurality also resulted in a difference in overall survival (1.98 months, 0.59-3.36).</p><p><strong>Conclusion: </strong>This study demonstrated that US individuals with metastatic prostate cancer residing rurally may have slightly poorer survival compared to patients from urban areas.</p>","PeriodicalId":54544,"journal":{"name":"Prostate","volume":" ","pages":"1052-1061"},"PeriodicalIF":2.6,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144112812","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multicenter External Validation and Optimization of a Proposed Nomogram for Prostate-Specific Membrane Antigen PET/CT Accuracy in Biochemical Recurrence.","authors":"Laura Chamorro Castillo, Inés Rivero Belenchón, Ignacio Puche Sanz, Rocío Saiz Marenco, Ana Victoria Ojeda Claro, Néstor Sánchez Martínez, Rafael Medina López, Alvaro Juárez Soto, Jose Luis Álvarez Ossorio, Emilio García Galisteo, Julia Carrasco Valiente, Bernardo Herrera Imbroda, Juan Moreno Jiménez, Juan Antonio Vallejo Casas, Antonio Rodríguez, Adrián Santiago Ortiz, Juan Pablo Campos Hernández, Enrique Gómez Gómez","doi":"10.1002/pros.24910","DOIUrl":"10.1002/pros.24910","url":null,"abstract":"<p><strong>Introduction: </strong>Prostate-specific membrane antigen (PSMA) PET/CT has been established as the standard imaging technique after biochemical recurrence (BCR) of prostate cancer (PCa). However, its availability is not widespread, thus, patient selection criteria are necessary. For this reason, a European nomogram was recently developed with the intention of helping to predict and identify those patients with BCR at high risk for a positive PSMA PET/CT. The aim of our study was to test the external validity of this nomogram in a large regional cohort of patients and its impact as a selective tool for patients with BCR who should undergo a PSMA PET/CT.</p><p><strong>Methodology: </strong>A multicenter, observational, and retrospective study to validate, calibrate, and readjust the European PSMA PET/CT positivity prediction nomogram in a cohort of patients with BCR after radical treatments for localized PCa. Clinical and demographic data were analyzed. We evaluated the detection rate of PSMA PET/CT, the association of different variables with a positive PSMA PET/CT, and the accuracy of the nomogram, summarized in an ROC curve and a clinical decision curve. The nomogram was then modified and improved for our cohort.</p><p><strong>Results: </strong>A cohort of 413 patients with BCR undergoing PSMA PET/CT was evaluated. Median age, PSA, and PSAdt were 66 years, 0.52 ng/mL, and 7 months, respectively. Median time to BCR was 34 months and the predominant ISUP was 3 (31%). Most patients underwent radical prostatectomy (88%). PSMA PET/CT was positive in 67% of patients, with pelvic involvement in 32% and 24% positivity outside the pelvis. The independent variables associated with a positive PSMA PET/CT were PSA value (OR: 1.94 (1.2-3.19), with a PSA level ≥ 0.5 ng/dL), and a PSA persistence after primary treatment (OR 2.95 (95% CI 1.37-7.14)). The original nomogram had a low predictive ability, with an AUC of 0.57 (95% CI: 0.52-0.62). It was necessary to adjust and calibrate this to obtain a novel nomogram with an AUC of 0.84 (95% CI 0.70-0.98). The DCA showed a greater net benefit from the use of this nomogram at intermediate threshold levels.</p><p><strong>Conclusion: </strong>The nomogram showed a low predictive ability in our external validation. Nevertheless, our novel nomogram demonstrated a moderate-high predictive ability, which could thus optimize the selection of BCR patients who are candidates for PSMA PET/CT.</p>","PeriodicalId":54544,"journal":{"name":"Prostate","volume":" ","pages":"1016-1023"},"PeriodicalIF":2.6,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144063294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of Area of Deprivation Index With Active Surveillance (AS) Utilization and Adherence to as Guidelines: Results From a Contemporary North American Cohort.","authors":"Alessandro Bertini, Alex Stephens, Alessio Finocchiaro, Viganò Silvia, Dinesh Arjun, Guivatchian Elnaz, Cusmano Nicholas, Giovanni Lughezzani, Nicolò Buffi, Ettore Di Trapani, Vincenzo Ficarra, Alberto Briganti, Andrea Salonia, Francesco Montorsi, Akshay Sood, Craig Rogers, Firas Abdollah","doi":"10.1002/pros.24911","DOIUrl":"10.1002/pros.24911","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Active Surveillance (AS) for Prostate Cancer (PCa) requires regular follow-up, raising concerns that socioeconomic barriers may result in underutilization or decreased adherence to AS guidelines. We examined the relationship between socioeconomic factors, measured by the Area Deprivation Index (ADI), and AS habits in a contemporary North American cohort.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;We included all the patients aged ≤ 75 years and diagnosed with low (ISUP GG = 1, PSA ≤ 10 ng/mL and cT1N0M0) and intermediate risk (ISUP GG = 2, PSA 10-20 ng/mL or cT2N0M0) PCa at Henry Ford Health (HFH) between 1995 and 2023. An ADI score was assigned to each patient based on their residential census block group, ranked as a percentile of deprivation relative to the national level. The higher the ADI, the more the area has a socioeconomic disadvantage. Logistic regression analysis tested the impact of ADI on AS utilization and adherence to AS guidelines. Only patients who underwent at least 1 PSA test per year and at least 1 biopsy every 4 years were considered as \"adherent to guidelines\".&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Our final cohort consisted of 4376 patients eligible for AS, 919 of whom actually underwent AS. Older patients (66 vs. 62 years, p &lt; 0.0001) and those diagnosed in more recent years (2017 vs. 2010, p &lt; 0.0001) had higher probability to undergo AS. Moreover, patients in the AS group more likely to be NHB (36% vs. 25%, p &lt; 0.0001), had higher ADI score (61 vs. 55, p &lt; 0.0001), more comorbidities according to Charlson Comorbidity Index (CCI) score, (19.5%% vs. 13.8%, p &lt; 0.0001) and higher probability to harbor low risk PCa (65.7% vs. 26.6%, p &lt; 0.0001), compared to patients who underwent active treatment. Among the 919 patients in AS, only 410 were \"adherent to guidelines\". Patients following guidelines were more likely to be NHW (64.1% vs. 52.8%, p &lt; 0.003), and had lower ADI percentile (55.5 vs. 66, p &lt; 0.0003). Furthermore, AS patients managed according to the prevailing guidelines received more PSAs tests (1.8 vs. 0.8, p &lt; 0.0001) and prostate biopsies (0.3 vs. 0.0, p &lt; 0.0001) per year, thus reporting both higher upgrading rates during AS (35.6% vs. 23%, p &lt; 0.0001) and an increased probability to undergo active treatment (48% vs. 27%, p &lt; 0.0001). At MVA, patients with a higher ADI score reported higher probability to undergo AS (OR: 1.06, 95% CI: 1.02-1.10, p = 0.004), but at the same time they were less likely to follow AS' guidelines (OR: 0.94, 95% CI: 0.89-0.99, p = 0.02).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;Patients in the most deprived areas had a higher likelihood of undergoing AS but were more prone to receive guideline-discordant care. This should be taken into consideration by physicians when recommending AS for those men living in the least advantaged neighborhoods. Our study highlights the need for targeted community reforms to enhance proper and informed AS utilization among socioeconomically disad","PeriodicalId":54544,"journal":{"name":"Prostate","volume":" ","pages":"1024-1035"},"PeriodicalIF":2.6,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144026862","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply - Letter to the Editor: Bimodal Imaging at MRI Fusion Prostate Biopsy Will Gain Further Importance in the Future.","authors":"Fabian Falkenbach, Fatima Ahmad-Sterkau, Mykyta Kachanov, Dirk Beyersdorff, Daniel Koehler, Francesca Ambrosini, Gernot Ortner, Tobias Maurer, Markus Graefen, Lars Budäus","doi":"10.1002/pros.24914","DOIUrl":"10.1002/pros.24914","url":null,"abstract":"","PeriodicalId":54544,"journal":{"name":"Prostate","volume":" ","pages":"1071-1072"},"PeriodicalIF":2.6,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144128406","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bimodal Imaging: Detection Rate of Clinically Significant Prostate Cancer Is Higher in MRI Lesions Visible to Transrectal Ultrasound.","authors":"Fu Feng, Zhanping Xu","doi":"10.1002/pros.24839","DOIUrl":"10.1002/pros.24839","url":null,"abstract":"","PeriodicalId":54544,"journal":{"name":"Prostate","volume":" ","pages":"1069-1070"},"PeriodicalIF":2.6,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144129612","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Effects of the Blood-Based S2,3PSA% Test on Prostate Cancer Screening: A Novel Approach to Reduce the Need for MRI and Unnecessary Biopsies.","authors":"Hikari Miura, Tomoko Hamaya, Tohru Yoneyama, Tadashi Shimoyama, Fumiyasu Tsushima, Kyo Togashi, Yuki Miura, Anna Yoneyama, Hiroyuki Sato, Sosuke Omizo, Kazuyuki Mori, Hirotake Kodama, Naoki Fujita, Teppei Okamoto, Hayato Yamamoto, Shingo Kakeda, Chikara Ohyama, Shingo Hatakeyama","doi":"10.1002/pros.24917","DOIUrl":"10.1002/pros.24917","url":null,"abstract":"<p><strong>Objective: </strong>Prostate-specific antigen (PSA)-based screening has reduced prostate cancer (PCa) mortality but is associated with overdiagnosis/overtreatment. We developed and evaluated a blood-based S2,3PSA% test to address the limitations of PSA-based screening for PCa.</p><p><strong>Methods: </strong>This retrospective study included men aged ≤ 75 years who underwent opportunistic PSA and S2,3PSA% screening between April 2022 and March 2023. Secondary screening was recommended for participants with PSA ≥ 2.0 ng/mL and S2,3PSA% ≥ 38.0%, or PSA ≥ 4.0 ng/mL. The primary outcome was the reduction in MRI utilization based on an S2,3PSA% cutoff of ≥ 38.0%. Secondary outcomes included the PCa detection rate, as well as reductions in prostate biopsies and medical costs.</p><p><strong>Results: </strong>Among 808 participants who underwent PSA and S2,3PSA% screening, 190 met the criteria for secondary screening. Of these, 72 underwent further evaluation, including MRI in 65 participants. MRI findings excluded 22 (33.8%) participants from requiring prostate biopsy. Ultimately, 25 participants underwent prostate biopsy, and PCa was diagnosed in 17 (68.0%), including 12 with clinically significant PCa. The combined use of PSA, S2,3PSA%, and MRI resulted in a 44% reduction in MRI use, a 63% reduction in unnecessary biopsies, and a 72% reduction in medical costs. Study limitations include the small sample size and lack of evaluation of participants with negative S2,3PSA% or MRI findings.</p><p><strong>Conclusions: </strong>S2,3PSA% screening may have potential as a tool to reduce the need for MRI, unnecessary biopsies, and medical costs.</p>","PeriodicalId":54544,"journal":{"name":"Prostate","volume":" ","pages":"1062-1068"},"PeriodicalIF":2.6,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12211547/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144128739","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Altered Ten Eleven Translocation Methylcytosine Dioxygenase Expression and DNA Hydroxymethylation in a Mouse Model of Prostate Cancer.","authors":"Matthew Aguilera, David L Klinkebiel, Victoryn Williams, Jeffrey Rovatti, Benjamin Purizhansky, Barbara A Foster, Adam R Karpf, Shannon R M Kinney","doi":"10.1002/pros.24912","DOIUrl":"10.1002/pros.24912","url":null,"abstract":"<p><strong>Background: </strong>DNA hydroxymethylation (5hmC) is known to be altered in human prostate cancer. An animal model is required to study the functional roles of the ten eleven translocation (TET) DNA dioxygenases and the 5hmC modification in prostate cancer development and progression.</p><p><strong>Methods: </strong>We characterized Tet expression, global genomic 5hmC, and genome-wide 5hmC patterns, and the transcriptome, in the TRansgenic Adenocarcinoma of Mouse Prostate (TRAMP) autochthonous model of prostate cancer.</p><p><strong>Results: </strong>We observed increased mRNA and protein levels of Tet1 in TRAMP samples, as compared to normal mouse prostate. Additionally, we found minimal expression of Tet2 mRNA overall, and Tet3 mRNA levels appeared similar in both sample types. However, TRAMP tumors expressed what appeared to be the inactive form of Tet3, versus the active form expressed in normal prostates. TRAMP tumors displayed global genomic hypohydroxymethylation (i.e., loss of 5hmC), and genome-wide analysis revealed widespread hypohydroxymethylation was interspersed with regions of locus-specific hyperhydroxymethylation (i.e., increased 5hmC). The differentially hydroxymethylated regions correlated with altered gene expression, and pathway analyses indicated that these genes often participate in oncogenic pathways.</p><p><strong>Conclusions: </strong>Tet expression and 5hmC patterns are altered in the TRAMP model and closely match what has been observed in human prostate cancer, suggesting that TRAMP is a suitable model to study the role of Tets and 5hmC in prostate cancer development and progression.</p>","PeriodicalId":54544,"journal":{"name":"Prostate","volume":" ","pages":"1036-1051"},"PeriodicalIF":2.6,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144041169","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence and Characteristics of Prostatic Utricles: A Retrospective MRI Study in Middle-Aged to Elderly Men.","authors":"Tomer Bashi, Shoni Kamshov, Adi Kidron, Sophie Barnes, Amihay Nevo, Snir Dekalo, Yuval Bar-Yosef","doi":"10.1002/pros.24907","DOIUrl":"10.1002/pros.24907","url":null,"abstract":"<p><strong>Background: </strong>Congenital urological malformations encompass a wide range of anomalies affecting the urinary tract and reproductive organs. MRI has emerged as a diagnostic tool in identifying these conditions. Prostatic utricle is an enlarged diverticulum in the posterior urethra, which results from incomplete degradation of the Müllerian ducts or decreased androgenic stimulation of the urogenital sinus. Prostatic utricle is an uncommon congenital anomalies, with 1% incidence in autopsy findings and clinical prevalence of 5% in urologic patients.</p><p><strong>Methods: </strong>This retrospective study analyzed 5819 prostate MRI interpretations from 4990 unique patients. The primary objective was to identify congenital abnormalities, focusing on the presence of a utricle and other related anomalies. Prostates suspected to have utricles were reevaluated by genitourinary specialized radiologist and utricles size were measured.</p><p><strong>Results: </strong>The study identified 127 patients positive for a utricle with an average age of 66 years at examination among the unique cohort. The average prostate size for patients with a utricle was 78.3 cc and the average utricle size was 0.4 cm³. Statistical analysis did not demonstrate any statistical trend between prostate size, age or PSA to utricle size. Additional congenital anomalies detected included one patient with a seminal vesicle cyst, one patient with right seminal vesicle agenesis and bilateral vas deferens agenesis, and two patients with ureterocele.</p><p><strong>Conclusion: </strong>The prevalence of prostate utricle within a cohort of 4990 middle-aged to elderly men is 2.54%.</p>","PeriodicalId":54544,"journal":{"name":"Prostate","volume":" ","pages":"1000-1004"},"PeriodicalIF":2.6,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12211538/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144041854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}